Table 3.
Changes in hemodynamic, arterial stiffness and metabolic parameters in control group during 12 months follow up
| Variable |
Placebo group |
||||
|---|---|---|---|---|---|
| Baseline | 4 month | p-value V1 vs V2 | 12 month | p-value V1 vs V3 | |
| Systolic BP (mm/Hg) |
133.0 ± 19.5 |
139.8 ± 19.3 |
0.091 |
125.4 ± 25.5 |
0.477 |
| Diastolic BP (mm/Hg) |
73.3 ± 14.1 |
75.0 ± 9.4 |
0.589 |
73.5 ± 11.9 |
0.842 |
| Aortic AP (mm/Hg) |
15.6 ± 9.3 |
20.2 ± 18.6 |
0.271 |
17.2 ± 12 |
0.587 |
| AI (%) |
29.9 ± 11.0 |
29.0 ± 11.5 |
0.625 |
34.6 ± 12.1 |
0.089 |
| Total Cholesterol (mg/dl) |
190.0 ± 38.5 |
186.2 ± 32.6 |
0.616 |
175.8 ± 30.6 |
0.024 |
| Triglycerides (mg/dl) |
140.8 ± 58.0 |
135.0 ± 57.6 |
0.588 |
146.2 ± 70.5 |
0.447 |
| HDL-cholesterol (mg/dl) |
47.8 ± 14.3 |
49.6 ± 15.3 |
0.329 |
49 ± 15.9 |
0.278 |
| LDL Cholesterol (mg/dl) |
110.8 ± 35.2 |
109.0 ± 25.7 |
0.786 |
103.3 ± 27.2 |
0.521 |
| ALP (U/l) |
74.3 ± 24.6 |
67.4 ± 19.6 |
0.065 |
71.5 ± 22.9 |
0.659 |
| ALT (U/l) |
34.9 ± 15.8 |
29.7 ± 16.3 |
0.120 |
32.1 ± 20.6 |
0.315 |
| AST (U/l) |
29.4 ± 8.4 |
27.4 ± 8.3 |
0.246 |
29.3 ± 12.9 |
0.957 |
| hs-CRP (mg/dl) |
1.0 ± 1.5 |
0.5 ± 0.5 |
0.139 |
0.5 ± 0.7 |
0.156 |
| Fasting glucose (mg/dl) |
98.1 ± 15.9 |
103.9 ± 18.5 |
0.015 |
98 ± 14.2 |
0.651 |
| Adiponectin (ng/ml) |
10251.8 ± 6610 |
10020.2 ± 5648 |
0.699 |
10255.8 ± 5704.4 |
0.529 |
| HOMA-IR | 5.4 ± 4.9 | 4.9 ± 7.5 | 0.682 | 4.97 ± 8 | 0.721 |